Ansell (ANN) H1 2025 earnings summary

Executive summary

• Achieved double-digit top and bottom-line growth in H1 FY25, with sales up 29.9% to $1,019.7m and EBIT up 62.9% to $127.4m, exceeding all performance objectives.

• KBU acquisition completed July 1, 2024, contributed $140.9m in sales and $34.8m EBIT; integration is ahead of schedule and expected to complete by end of FY25.

• APIP delivered $22m in H1 FY25 savings, with $43m realized over the past 12 months, supporting margin expansion.

• Increased Adjusted EPS guidance to US118¢–US128¢ for FY25, reflecting strong performance and balance sheet flexibility.

• Continued investment in long-term growth, differentiation, and sustainability initiatives.

Financial highlights

• Revenue: $1,019.7m (up 29.9% year-over-year; organic constant currency up 12.5%).

• EBIT: $127.4m (up 62.9% year-over-year; organic constant currency up 20.9%); EBIT margin improved to 12.5% from 10.0%.

• Adjusted EPS: 55.7¢ (up 35.5% year-over-year); statutory EPS up 143.9% to 37.8¢.

• Operating cash flow: $129.8m reported, with cash conversion at 104%.

• Interim dividend declared at US22.20¢ per share, payout ratio 40%.

Outlook and guidance

• FY25 Adjusted EPS guidance raised to US118¢–US128¢.

• Continued organic constant currency sales growth expected in H2, though at a slower pace due to one-time H1 benefits and muted manufacturing demand.

• Pricing actions and cost synergies to offset raw material inflation and tariff increases; limited cost impact expected in H2.

• CapEx guidance maintained at $60m–$70m, including India Surgical facility investment.

• Dividend payout policy maintained at 40–50% of net profit (excluding one-offs).